|
|
Article: Par Pharmaceutical Announces Agreement With GlaxoSmithKline to Settle Imitrex(R) Injection Patent Litigation.
- Article from:
- PR Newswire
- Article date:
- November 13, 2006
CopyrightCOPYRIGHT 2006 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Settlement Agreement with GSK Resolves Imitrex(R) Injection Patent Litigation and Permits Par to Launch Generic Version in 2008
WOODCLIFF LAKE, N.J., Nov. 13 /PRNewswire-FirstCall/ -- Par Pharmaceutical Companies, Inc. today announced that its partner, Spectrum Pharmaceuticals, Inc., has entered into a settlement agreement with GlaxoSmithKline (GSK) that resolves U.S. patent litigation related to GSK's Imitrex(R) Injection, thereby eliminating the inherent uncertainty and costs of litigation. The confidential terms of the settlement, which remain subject to government review, permit Par to sell generic versions of certain sumatriptan injection products with an ...